
LFCR Stock Forecast & Price Target
LFCR Analyst Ratings
Bulls say
Lifecore Biomedical Inc. is demonstrating a strong financial outlook, with projected EBITDA increasing from $24.4 million at a 16.8% margin in FY26 to $27.3 million at a 19.1% margin in FY27, indicating significant improvement in operational efficiency. Furthermore, free cash flow (FCF) has turned positive, with expectations of growing from $5.1 million in FY26 to $6.0 million in FY27, reflecting the company's ability to generate cash after capital expenditures. These key metrics suggest strong revenue growth and enhancing profitability, supporting a favorable outlook for the company's stock.
Bears say
Lifecore Biomedical's outlook is negatively impacted by its anticipated slow revenue growth, with projections indicating no meaningful increases until calendar year 2027. The company is also facing a high leverage ratio, which contributes to concerns over its financial stability and warrants a discount compared to industry peers. Additionally, while the company expects a 10% market growth figure in fill/finish services, this rate is considered optimistic given a projected market decline influenced by the inclusion of small molecule injectables.
This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.
LFCR Analyst Forecast & Price Prediction
Start investing in LFCR
Order type
Buy in
Order amount
Est. shares
0 shares